Douglas A. Melton

Doug Melton
Doug Melton
Born	Douglas A. Melton
Nationality	American
Alma mater	University of Illinois at Urbana–Champaign (BS); University of Cambridge (BA, PhD);
Known for	Research on cure for type 1 diabetes
Awards	George Ledlie Prize; Richard Lounsbery Award (1995); Eliot P. Joslin Medal; NAS member (1995); Marshall Scholarship;
	Scientific career
Fields	Stem cells; Developmental biology;
Institutions	Harvard University; Howard Hughes Medical Institute;
Thesis	The expression of transfer RNA genes to other DNAs microinjected into Xenopus oocytes (1979)
Doctoral advisor	John Gurdon
Notable students	Richard P. Harvey (postdoc); Clifford Tabin (postdoc);
Website	www.scrb.harvard.edu/lab/50/home; hsci.harvard.edu/people/douglas-melton-phd;

Douglas A. Melton is an American medical researcher who is the Xander University Professor at Harvard University, and was an investigator at the Howard Hughes Medical Institute until 2022. Melton serves as the co-director of the Harvard Stem Cell Institute and was the first co-chairman (with David Scadden) of the Harvard University Department of Stem Cell and Regenerative Biology. Melton is the founder of several biotech companies including Gilead Sciences, Ontogeny (now Curis), iPierian (now True North Therapeutics Archived 2017-06-29 at the Wayback Machine), and Semma Therapeutics. Melton holds membership in the National Academy of the Sciences, the American Academy of Arts and Sciences, and is a founding member of the International Society for Stem Cell Research.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.